SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 2168700

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 2168700

Chronic Pain - Epidemiology Forecast - 2036

PUBLISHED:
PAGES: 184 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 3990
PDF & Excel (2-3 User License)
USD 4988
PDF & Excel (Site License)
USD 6982
PDF & Excel (Global License)
USD 8977

Add to Cart

Chronic Pain Insights and Trends

  • In 2025, the total number of diagnosed prevalent cases of chronic pain in the 7MM was around 115 million. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases, contributing approximately 45 million cases.
  • Among EU4 and the UK, Germany accounted for the highest diagnosed prevalence of chronic pain, with ~15 million of the total cases. In contrast, with only approximately 10 million cases, Spain reported the lowest diagnosed prevalence of chronic pain in 2025.
  • The persistent predominance of females suggests a greater chronic pain burden among women in 7MM, potentially reflecting differences in the prevalence of pain-associated musculoskeletal conditions, aging patterns, and healthcare-seeking behavior.
  • Chronic low back pain and osteoarthritis remain major contributors to the chronic pain burden across the 7MM, while migraine, neuropathic pain, fibromyalgia, and rheumatoid arthritis-associated pain represent additional important underlying conditions contributing to the overall patient population.
  • The treated population is expanding in parallel with the diagnosed population, demonstrating that the growing epidemiological burden is translating into an increasingly large actively managed patient pool. This is important from a market perspective because it indicates that future growth is not dependent solely on new diagnosis; existing diagnosed patients are also contributing to sustained treatment demand.
  • The severity profile shows a substantial concentration of patients with moderate and severe chronic pain, with both segments projected to expand over the forecast period. This indicates that growth is not limited to lower-intensity symptoms and highlights a clinically relevant opportunity for stronger, sustained, or multimodal pain-control therapies for patients with greater disease burden.

DelveInsight's "Chronic Pain - Epidemiology Forecast - 2036" report delivers an in depth understanding of chronic pain, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered:

North America: The United States

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

Chronic Pain Understanding

Chronic Pain Overview and Diagnosis

Chronic pain is a complex and persistent condition defined as pain lasting beyond the normal healing period, typically for more than 3-6 months. It affects a substantial proportion of the adult population and is associated with significant physical, psychological, and socioeconomic burden. Chronic pain may arise from tissue injury, disease, nerve damage, or altered pain processing, and is frequently accompanied by comorbid conditions such as depression and anxiety, which further impair quality of life and functional capacity. The condition is also associated with increased healthcare utilization, reduced productivity, opioid misuse, and elevated mortality risk.

The diagnosis of chronic pain requires a comprehensive and multidisciplinary evaluation aimed at identifying the underlying cause, determining the predominant pain mechanism, and assessing the impact of pain on physical, psychological, and social functioning. Because chronic pain may arise from musculoskeletal, neuropathic, inflammatory, visceral, or nociplastic mechanisms, diagnosis is based on a combination of clinical assessment and targeted diagnostic investigations. A thorough physical examination helps identify structural, neurological, or inflammatory abnormalities that may contribute to chronic pain. Examination typically includes assessment of posture, gait, joint range of motion, muscle strength, tenderness, swelling, sensory changes, reflexes, and signs of nerve compression or musculoskeletal dysfunction.

Chronic Pain Epidemiology

Key Findings from Chronic Pain Epidemiological Analysis and Forecast

  • According to DelveInsight's analysis, more than 20 million males and 25 million females were affected with chronic pain in the US in 2025. The continued increase across both genders by 2036 indicates an expanding chronic pain patient pool in the US, with the higher burden among females potentially reflecting differences in the prevalence of pain-associated conditions and healthcare utilization.
  • Across EU4 and the UK, approximately 50 million diagnosed prevalent cases were reported in 2025. Germany accounted for the largest share, contributing around 10 million diagnosed prevalent cases, followed by the France.
  • According to DelveInsight's estimates, Moderate chronic pain accounted for the highest number of diagnosed prevalent cases across EU4 and the UK in 2025, with approximately 25 million cases, followed by Mild (10 million cases) and Severe (15 million cases).
  • Japan accounted for nearly 20 million diagnosed prevalent cases of chronic pain in 2025, representing only a small proportion of the total prevalent patient population.

Industry Experts and Physician Views for Chronic Pain

To keep up with chronic pain patient trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on chronic pain epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 20+ KOLs to gather insights at country level. Leading centers such as Harvard University and Friedrich Schiller University Jena, Brigham and Women's Hospital, Aichi Medical University, among others, were consulted to validate clinical practices, treatment patterns, and emerging therapeutic perspectives.

Scope of the Report:

  • The report covers a segment of an executive summary, a descriptive overview of chronic pain, explaining its causes, signs, symptoms, and pathogenesis.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

  • Chronic pain Patient Population Forecast
  • Country-wise Epidemiology Distribution

Report Key Strengths

  • Epidemiology-based (Epi-based) Bottom-up Forecasting
  • Artificial Intelligence (AI)-Enabled Market Research Report
  • 11-Year Forecast
  • Patient Burden Trends (by geography)
  • The 7MM Coverage

FAQs:

  • What are the disease risks, burdens, and unmet needs of chronic pain?
  • What will be the growth opportunities across the 7MM concerning the patient population with chronic pain?
  • What is the chronic pain prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
  • What is the historical and forecasted chronic pain patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

  • Insights on chronic pain burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
  • Clear methodology, validated assumptions, and data-driven rationale to assess the chronic pain epidemiology analysis and patient population trends.
Product Code: DIEI1124

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology Overview at a Glance

  • 4.1. Patient Share (%) Distribution of Chronic Pain in the 7MM in 2025
  • 4.2. Patient Share (%) Distribution of Chronic Pain in the 7MM in 2036

5. Epidemiology Forecast Methodology

6. Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Types of Chronic Pain
  • 6.3. Classification of Chronic Pain
  • 6.4. Sign and Symptoms of Chronic Pain
  • 6.5. Causes and Risk factors of Chronic Pain
    • 6.5.1. Causes of Chronic Pain
  • 6.6. Pathophysiology of Chronic Pain
  • 6.7. Diagnosis of Chronic Pain
    • 6.7.1. Medical History Review
    • 6.7.2. Physical Examination
    • 6.7.3. Pain Assessment Tools
    • 6.7.4. X-rays
    • 6.7.5. Magnetic Resonance Imaging (MRI)
    • 6.7.6. Computed Tomography (CT) Scans
    • 6.7.7. Electromyography (EMG) and Nerve Conduction Studies
    • 6.7.8. Blood Tests
    • 6.7.9. Bone Scans
    • 6.7.10. Nerve Blocks and Diagnostic Injections
    • 6.7.11. Psychological Evaluation
    • 6.7.12. Ultrasound
  • 6.8. Diagnostic Algorithm
  • 6.9. Differential Diagnosis
  • 6.10. Diagnostics guidelines
    • 6.10.1. The American Headache Society Consensus Statement, 2021
    • 6.10.2. American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity
    • 6.10.3. VA/DoD Clinical Practice Guidelines Use of Opioids in the Assessment of Chronic Pain, 2022
    • 6.10.4. German Society of Neurology Guidelines for Neuropathic Pain, 2021
    • 6.10.5. NICE Guidelines for the Assessment and Diagnosis of Chronic Pain (Primary and Secondary) in Adults, 2021
    • 6.10.6. NICE Guidelines for lower back pain and sciatica, 2020
    • 6.10.7. Japanese Clinical Practice Guidelines for the Management of Chronic Pain, 2021
    • 6.10.8. Japanese Orthopedic Association Clinical Practice Guideline for Low Back Pain (Journal of Orthopaedic Science, 2021)

7. Patient Journey

8. Epidemiology and Patient Population

  • 8.1. Key Findings
  • 8.2. Assumptions and Rationale: 7MM
    • 8.2.1. United States
    • 8.2.2. EU4 and the UK
      • 8.2.2.1. Germany
      • 8.2.2.2. France
      • 8.2.2.3. Italy
      • 8.2.2.4. Spain
      • 8.2.2.5. United Kingdom
    • 8.2.3. Japan
  • 8.3. Total Diagnosed Prevalent Cases of Chronic Pain in the 7MM
  • 8.4. The US
    • 8.4.1. Total Prevalent Cases of Chronic Pain in the US
    • 8.4.2. Total Diagnosed Prevalent Cases of Chronic Pain in the US
    • 8.4.3. Severity-specific Diagnosed Prevalent Cases of Chronic Pain in the US
    • 8.4.4. Gender-specific Diagnosed Prevalent Cases of Chronic Pain in the US
    • 8.4.5. Age-specific Diagnosed Prevalent Cases of Chronic Pain in the US
    • 8.4.6. Cause-specific Diagnosed Prevalent Cases of Chronic Pain in the US
    • 8.4.7. Total Treated Cases of Chronic Pain in the US
  • 8.5. EU4 and the UK
    • 8.5.1. Total Prevalent Cases of Chronic Pain in EU4 and the UK
    • 8.5.2. Total Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
    • 8.5.3. Severity -specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
    • 8.5.4. Gender-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
    • 8.5.5. Age-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
    • 8.5.6. Cause-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
    • 8.5.7. Total Treated Cases of Chronic Pain in EU4 and the UK
  • 8.6. Japan
    • 8.6.1. Total Prevalent Cases of Chronic Pain in Japan
    • 8.6.2. Total Diagnosed Prevalent Cases of Chronic Pain in Japan
    • 8.6.3. Severity -specific Diagnosed Prevalent Cases of Chronic Pain in Japan
    • 8.6.4. Gender-specific Diagnosed Prevalent Cases of Chronic Pain in Japan
    • 8.6.5. Age-specific Diagnosed Prevalent Cases of Chronic Pain in Japan
    • 8.6.6. Cause-specific Diagnosed Prevalent Cases of Chronic Pain in Japan
    • 8.6.7. Total Treated Cases of Chronic Pain in Japan

9. Key Opinion Leaders' Views

  • 9.1. Expert/KOL Interview Highlights

10. Appendix

  • 10.1. Bibliography
  • 10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

Product Code: DIEI1124

List of Tables

  • Table 1: Summary of Chronic Pain Epidemiology (2025-2036)
  • Table 2: Examination & Testing for Diagnosing Chronic Pain (Japan Clinical Practice Guidelines)
  • Table 3: Pain-related Questionnaires & Scales
  • Table 4: Guidelines for Chronic Neuropathic Pain
  • Table 5: Total Diagnosed Prevalent Cases of Chronic Pain in the 7MM, in Thousands (2022-2036)
  • Table 6: Total Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Table 7: Total Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Table 8: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Table 9: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Table 10: Age-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Table 11: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Table 12: Total Treated Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Table 13: Total Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Table 14: Total Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Table 15: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Table 16: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Table 17: Age-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Table 18: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Table 19: Total Treated Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Table 20: Total Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Table 21: Total Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Table 22: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Table 23: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Table 24: Age-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Table 25: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Table 26: Total Treated Cases of Chronic Pain in Japan, in Thousands (2022-2036)

List of Figures

  • Figure 1: Types of Chronic Pain
  • Figure 2: Classification of Chronic Pain
  • Figure 3: Causes of Chronic Pain
  • Figure 4: Risk factors of Chronic Pain
  • Figure 5: Pathophysiology of Chronic Pain
  • Figure 6: Diagnostic Algorithm of Chronic Pain
  • Figure 7: Total Diagnosed Prevalent Cases of Chronic Pain in the 7MM, in Thousands (2022-2036)
  • Figure 8: Total Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Figure 9: Total Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Figure 10: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Figure 11: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Figure 12: Age-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Figure 13: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Figure 14: Total Treated Cases of Chronic Pain in the US, in Thousands (2022-2036)
  • Figure 15: Total Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Figure 16: Total Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Figure 17: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Figure 18: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Figure 19: Age-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Figure 20: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Figure 21: Total Treated Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
  • Figure 22: Total Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Figure 23: Total Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Figure 24: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Figure 25: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Figure 26: Age-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Figure 27: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
  • Figure 28: Total Treated Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!